Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Relapse assessment following allogeneic SCT in patients with MDS and AML.

Annals of hematology - 1 Jul 2014

Christopeit Maximilian, Kröger Nicolaus, Haferlach Torsten, Bacher Ulrike

Abstract excerpt

Options to pre-emptively treat impending relapse of myelodysplastic syndromes (MDS) and acute myeloid leukaemia (AML) after allogeneic haematopoietic stem cell transplantation (allo-SCT) continuously increase. In recent years, the spectrum of diagnostic methods and parameters to perform post-tran...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to WT1 gene
Share to Hematopoietic Stem Cell Transplantation
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Myelodysplastic Syndromes

Share to Nucleophosmin

Share to Secondary Prevention

Share to Transplantation, Homologous

Source

Identifiers

PMID: 24671364
DOI: 10.1007/s00277-014-2046-8

Genes

SCT
NPM1
WT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-24671364-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Relapse assessment following allogeneic SCT in patients with MDS and AML.PMID 24671364Read ↗

Early post-transplant molecular residual disease predicts outcomes in myelodysplastic neoplasms and myelodysplastic neoplasms/acute myeloid leukemia undergoing allogeneic transplantationSemantic proximity Read ↗

The current and future role of stem cells in myelodysplastic syndrome therapies.Semantic proximity Read ↗

Minimal residual disease diagnostics in myeloid malignancies in the post transplant period.Semantic proximity Read ↗

Patient-Specific Measurable Residual Disease Markers Predict Outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms.Semantic proximity Read ↗

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid LeukemiaSemantic proximity Read ↗

Molecular methods used for detection of minimal residual disease following hematopoietic stem cell transplantation in myeloid disorders.Semantic proximity Read ↗

The Prognostic Value of Early Detection of Minimal Residual Disease as Defined by Flow Cytometry and Gene Mutation Clearance for Myelodysplastic Syndrome Patients After Myeloablative Allogeneic Hematopoietic Stem-Cell TransplantationSemantic proximity Read ↗

Diagnosing recipient- vs. donor-derived posttransplant myelodysplastic neoplasm via targeted single-cell mutational profiling.Semantic proximity Read ↗

Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.Semantic proximity Read ↗

Evaluation of the risk of therapy-related MDS/AML after autologous stem cell transplantation.Semantic proximity Read ↗

Acute Myeloid Leukemia Patients With Myelodysplasia-Related Gene Mutations Benefit From Post-Transplant Hypomethylating Agent Maintenance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.